Compare MGPI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGPI | LXRX |
|---|---|---|
| Founded | 1941 | 1995 |
| Country | United States | United States |
| Employees | 267 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.8M | 547.4M |
| IPO Year | 1994 | 2000 |
| Metric | MGPI | LXRX |
|---|---|---|
| Price | $18.86 | $1.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $30.00 | $3.23 |
| AVG Volume (30 Days) | 296.5K | ★ 2.3M |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | N/A | ★ 21.25 |
| EPS | N/A | ★ N/A |
| Revenue | $19,782,000.00 | ★ $31,081,000.00 |
| Revenue This Year | N/A | $56.61 |
| Revenue Next Year | $5.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2481.48 |
| 52 Week Low | $18.42 | $0.32 |
| 52 Week High | $35.45 | $1.83 |
| Indicator | MGPI | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 22.66 | 64.63 |
| Support Level | N/A | $1.07 |
| Resistance Level | $25.99 | $1.65 |
| Average True Range (ATR) | 1.02 | 0.10 |
| MACD | -0.81 | 0.02 |
| Stochastic Oscillator | 7.80 | 93.42 |
MGP Ingredients Inc is a producer and supplier of premium distilled spirits and specialty wheat protein and starch food ingredients. MGP also produces high-quality industrial alcohol for use in both food and non-food applications. It operates in three segments: Distillery Solutions, Branded Spirits Segment, and Ingredient Solutions. Distillery Solutions provides distillery co-products, such as distillers feed, fuel grade alcohol, and corn oil: and warehouse services, including barrel put away, storage, and retrieval services. It derives its revenue from the Distillery Solutions segment.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.